Madrigal Pharmaceuticals (MDGL) Accumulated Depreciation & Amortization (2011 - 2016)

Madrigal Pharmaceuticals (MDGL) has 6 years of Accumulated Depreciation & Amortization data on file, last reported at $21.1 million in Q1 2016.

• Quarterly Accumulated Depreciation & Amortization rose 1.98% year-over-year to $21.1 million in Q1 2016, while the trailing twelve-month figure through Mar 2016 was $21.1 million (up 1.98% YoY) and the FY2015 annual result came in at $21.1 million, up 3.23% from the prior year.
• Accumulated Depreciation & Amortization was little changed at $21.1 million in Q1 2016 per MDGL's latest filing, from $21.1 million in the prior quarter.
• Across five years, Accumulated Depreciation & Amortization topped out at $21.1 million in Q4 2015 and bottomed at $19.8 million in Q2 2012.
• The 5-year median for Accumulated Depreciation & Amortization is $20.5 million (2013), against an average of $20.5 million.
• The widest annual swing landed in 2012, when Accumulated Depreciation & Amortization gained 3.81%; it then slipped 0.32% in 2014.
• Tracing MDGL's Accumulated Depreciation & Amortization over 5 years: stood at $20.1 million in 2012, then advanced by 1.89% to $20.5 million in 2013, then gained by 0.03% to $20.5 million in 2014, then climbed by 3.23% to $21.1 million in 2015, then dropped by 0.4% to $21.1 million in 2016.
• Per Business Quant, the three latest MDGL Accumulated Depreciation & Amortization figures stand at $21.1 million (Q1 2016), $21.1 million (Q4 2015), and $21.0 million (Q3 2015).

Peer Comparison